RCUS (Arcus Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

RCUS (Arcus Biosciences, Inc.) Stock Financials & Earnings | Market Cap Arena

RCUSArcus Biosciences, Inc.

Mkt Cap$2B

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Revenue (TTM)$247M

Net Income (TTM)-$353M

EPS (TTM)-$3.29

Free Cash Flow (TTM)-$484M

Gross Margin98.0%

Op. Margin-156.3%

Net Margin-142.9%

FCF Margin-196.0%

P/S Ratio (TTM)9.9x

P/E Ratio (TTM)—

YoY Rev Growth-4.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$25M	$25M	-$86M
Q2 23	$29M	$29M	-$83M
Q3 23	$32M	$32M	-$80M
Q4 23	$31M	$31M	-$91M
Q1 24	$145M	$145M	-$16M
Q2 24	$39M	$39M	-$106M
Q3 24	$48M	$48M	-$105M
Q4 24	$26M	$26M	-$103M
Q1 25	$28M	$28M	-$122M
Q2 25	$160M	$160M	-$8M
Q3 25	$26M	$24M	-$142M
Q4 25	$33M	$30M	-$114M

Valuation

Quarter	P/S	P/E
Q1 23	20.7x	—
Q2 23	20.3x	—
Q3 23	20.5x	—
Q4 23	21.0x	—
Q1 24	10.3x	—
Q2 24	9.9x	—
Q3 24	9.3x	—
Q4 24	9.5x	—
Q1 25	17.4x	—
Q2 25	9.4x	—
Q3 25	10.2x	—
Q4 25	9.9x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$98M	-$101M
Q2 23	-$57M	-$62M
Q3 23	-$63M	-$73M
Q4 23	-$88M	-$94M
Q1 24	-$2M	-$6M
Q2 24	-$94M	-$94M
Q3 24	$26M	$25M
Q4 24	-$100M	-$101M
Q1 25	-$132M	-$133M
Q2 25	-$133M	-$133M
Q3 25	-$97M	-$97M
Q4 25	-$120M	-$121M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$3M
Q2 23	$5M
Q3 23	$10M
Q4 23	$6M
Q1 24	$4M
Q2 24	$0
Q3 24	$1M
Q4 24	$1M
Q1 25	$1M
Q2 25	$0
Q3 25	$0
Q4 25	$1M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+38.9%	+30.6%
Q2 23	+7.4%	+16.7%
Q3 23	-3.0%	+8.7%
Q4 23	-7.9%	+12.9%
Q1 24	+480.0%	+45.0%
Q2 24	+34.5%	+29.5%
Q3 24	+50.0%	+36.6%
Q4 24	-16.1%	+5.7%
Q1 25	-80.7%	-6.8%
Q2 25	+310.3%	+15.9%
Q3 25	-45.8%	+9.8%
Q4 25	+26.9%	+14.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$18M	62.1%
Q3 23	$18M	56.3%
Q4 23	$0	0.0%
Q1 24	$20M	13.8%
Q2 24	$20M	51.3%
Q3 24	$19M	39.6%
Q4 24	$17M	65.4%
Q1 25	$16M	57.1%
Q2 25	$15M	9.4%
Q3 25	$14M	53.8%
Q4 25	$15M	45.5%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$81M	$30M
Q2 23	$84M	$28M
Q3 23	$82M	$30M
Q4 23	$93M	$29M
Q1 24	$109M	$32M
Q2 24	$115M	$30M
Q3 24	$123M	$30M
Q4 24	$101M	$28M
Q1 25	$122M	$28M
Q2 25	$139M	$29M
Q3 25	$141M	$27M
Q4 25	$121M	$26M

Revenue Segments

Quarter	License and Development Services Revenue	Other Collaboration Revenue
Q1 23	$17M	$8M
Q2 23	$19M	$10M
Q3 23	$22M	$10M
Q1 24	$135M	$10M
Q2 24	$28M	$11M
Q3 24	$41M	$7M
Q1 25	$20M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$238M	$716M	$954M
Q2 23	$230M	$700M	$930M
Q3 23	$184M	$615M	$799M
Q4 23	$127M	$632M	$759M
Q1 24	$185M	$810M	$995M
Q2 24	$156M	$813M	$969M
Q3 24	$201M	$888M	$1.1B
Q4 24	$150M	$828M	$978M
Q1 25	$192M	$805M	$997M
Q2 25	$248M	$663M	$911M
Q3 25	$238M	$593M	$831M
Q4 25	$222M	$759M	$981M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	73M	+0.6%
Q2 23	73M	+0.3%
Q3 23	75M	+1.9%
Q4 23	75M	+0.5%
Q1 24	86M	+14.9%
Q2 24	91M	+5.7%
Q3 24	91M	+0.3%
Q4 24	92M	+0.3%
Q1 25	98M	+7.3%
Q2 25	107M	+8.2%
Q3 25	107M	+0.0%
Q4 25	107M	+0.8%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 16	—	—
FY 17	—	—
FY 18	$77K	108
FY 19	$108K	139
FY 20	$331K	236
FY 21	$1M	366
FY 22	$224K	500
FY 23	$203K	577
FY 24	$411K	627
FY 25	$1K	200K